ClinicalTrials.gg
CompletedNCT01666951Updated Jul 7, 2015Results posted

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

A Phase 2 interventional study of LCP-Tacro tablets and Prograf in Renal Failure, sponsored by Veloxis Pharmaceuticals. Completed at 13 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-07-07.

Sponsored by Veloxis Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing tacrolimus in Renal Insufficiency — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Renal Insufficiency.

Enrollment
14th of 17
36 · median 50
Started
2012
the only one that year
Phase 2
3 of 17
none open now
Registered
12th of 17
by date
Lead sponsor
8 of 17
Veloxis Pharmaceuticals

Among the 17 studies testing tacrolimus in Renal Insufficiency, this one is the 14th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 12th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 17 studies testing tacrolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing tacrolimus in Renal Insufficiency as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.

Read the detailed description

This is a 2-arm , parallel group, prospective, double-blind, double-dummy, multicenter,clinical trial to evaluate the pharmacokinetics of LCP-Tacro tablets once daily in comparison to Prograf capsules twice-daily after kidney transplantation.

03

Conditions studied

  • Renal Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Give written consent
  • Male and female subjects between the ages of 18 and 70 years, inclusive
  • Must be receiving primary or secondary renal allograft from a deceased donor or non- HLA identical living donor
  • must have a negative pregnancy test
  • Must have negative cross-match test and be ABO-compatible
  • Must be able to swallow tablets and capsules

Exclusion criteria

Exclusion criteria

  • Recipients of any previous nonrenal or concurrent transplant
  • Have panel reactive antibody >50%
  • Any condition that may affect study drug absorption \<18 kg/m2 or > 45 kg/m2
  • History of alcohol abuse with less than 6 months of sobriety
  • History of recreational drug abuse with less than 6 months of documented abstinence
  • Screening 12-lead demonstrating CS abnormalities (including prolongation)
  • and are either pregnant, lactating, planning to become pregnant or with a positive serum or urine pregnancy test
  • Subjects (male or female) with who are unwilling/unable to use a double-barrier method
  • Oral temperature (prior to study drug dosing) of 38.0ºC or higher
  • CS active infections (eg, those requiring hospitalization, or as judged by the Investigator)
  • Known hereditary immunodeficiency
  • or with a history of malignancies (within the last 5 years) with the exception of local, noninvasive, fully excised cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, or cervical carcinoma in situ
  • Expect to receive within 2 months after randomization, or have received within 3 months prior to screening, any of the following: sirolimus, everolimus, belatacept, or cyclophosphamide
  • Any psychiatric or medical condition that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
  • Clinically symptomatic CHF or documented EJF of less than 45%
  • Significant , pulmonary restrictive disease or significant pulmonary hypertension
  • Enrolled in another drug or device study, or who are less than 30 days since discontinuing
  • Laboratory variables that are abnormal (outside laboratory reference range) and CS
  • Positive results of any of the following serological tests: (HIV)-1 antibody, virus (HBV) surface antigen (HBsAg), anti-hepatitis B core antibody (HBcAb), and anti- virus (HCV) antibody (HCV Ab)
  • Subjects who have had primary focal segmental glomerulosclerosis
  • Donor parameters must not include any of the following known conditions:

Donor with positive serological test result for HIV-1, HBV or HCV Donor with history of malignant disease (current or historical) Cold ischemia time >30 hours Non-heart-beating donor

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    LCP-Tacro

    LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)

    Drug: LCP-Tacro tablets

  • Active comparator
    Prograf

    Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)

    Drug: Prograf

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (AUC) was evaluated on Day 1 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.

    Time frame: 1 days

  2. Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (AUC) was evaluated on Day 14 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.

    Time frame: 14 days

  3. Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (AUC) was evaluated on Day 28 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.

    Time frame: 28 days

  4. Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 1 in adult de novo kidney recipients.

    Time frame: 1 days

  5. Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 14 in adult de novo kidney recipients.

    Time frame: 14 days

  6. Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 28 in adult de novo kidney recipients.

    Time frame: 28 days

  7. Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (Tmax) was evaluated on Day 1 in adult de novo kidney recipients.

    Time frame: 1 days

  8. Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (Tmax) was evaluated on Day 14 in adult de novo kidney recipients.

    Time frame: 14 days

  9. Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (Tmax) was evaluated on Day 28 in adult de novo kidney recipients.

    Time frame: 28 days

  10. Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (Fluctuation) was evaluated on Day 14 in adult de novo kidney recipients.

    Time frame: 14 days

  11. Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation

    The pharmacokinetic parameter (Fluctuation) was evaluated on Day 28 in adult de novo kidney recipients.

    Time frame: 28 days

Other outcomes

  1. Daytime, Nighttime and Overnight Systolic Blood Pressure (SBP) on Day 14.

    At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 14.

    Time frame: 14 days

  2. Daytime, Nighttime Overnight Systolic Blood Pressure (SBP) on Day 28.

    At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Day 28.

    Time frame: 28 days

  3. Ratio of Nighttime to Daytime Systolic Blood Pressure (SBP) on Day 14.

    At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 14.

    Time frame: 14 days

  4. Ratio of Nighttime to Daytime Systolic Blood Pressure (SBP) on Day 28.

    At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 28.

    Time frame: 28 days

  5. Evaluation of the Short-term Efficacy of LCP-Tacro After the Start of Dosing.

    The efficacy is measured by the number of treatment failures defined as all-cause mortality, Graft Failure, Biopsy Proven Acute Rejection (BPAR) and Lost to follow up.

    Time frame: 30 days

07

Results

Posted Jul 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneLCP-TacroPrograf
Started1818
Completed1717
Not completed11
Withdrew: Not dosed11

Outcome measures

Other pre-specifiedDaytime, Nighttime and Overnight Systolic Blood Pressure (SBP) on Day 14.

At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 14.

Time frame:
14 days
Reported as:
Mean · mmHg
Daytime, Nighttime and Overnight Systolic Blood Pressure (SBP) on Day 14.
mmHgLCP-TacroPrograf
Daytime SBP140.96 ± 10,311131.54 ± 13.835
Nighttime SBP140.69 ± 9.147133.38 ± 17.875
Overnight SBP140.80 ± 10.347132.54 ± 18.127
Other pre-specifiedDaytime, Nighttime Overnight Systolic Blood Pressure (SBP) on Day 28.

At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Day 28.

Time frame:
28 days
Reported as:
Mean · mmHg
Daytime, Nighttime Overnight Systolic Blood Pressure (SBP) on Day 28.
mmHgLCP-TacroPrograf
Daytime SBP139.05 ± 14.722130.84 ± 15.754
Nighttime SBP137.18 ± 13.283129.09 ± 16.447
Overnight SBP136.11 ± 13.539127.70 ± 16.599
PrimaryPharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (AUC) was evaluated on Day 1 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.

Time frame:
1 days
Reported as:
Mean · ng*hr/mL
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation
ng*hr/mLLCP-TacroPrograf
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation382.72 ± 233.84147.82 ± 85.31
PrimaryPharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (AUC) was evaluated on Day 14 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.

Time frame:
14 days
Reported as:
Mean · ng*hr/mL
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation
ng*hr/mLLCP-TacroPrograf
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation371.43 ± 133.85244.63 ± 66.92
PrimaryPharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (AUC) was evaluated on Day 28 in adult de novo kidney recipients. Samples were collected from 0 to 24 hours post dose.

Time frame:
28 days
Reported as:
Mean · ng*hr/mL
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation
ng*hr/mLLCP-TacroPrograf
Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation357.39 ± 146.64205.79 ± 36.25
PrimaryPharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 1 in adult de novo kidney recipients.

Time frame:
1 days
Reported as:
Mean · ng/mL
Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation
ng/mLLCP-TacroPrograf
Cmax32.68 ± 20.5112.97 ± 7.08
C2413.32 ± 8.895.72 ± 5.28
PrimaryPharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 14 in adult de novo kidney recipients.

Time frame:
14 days
Reported as:
Mean · ng/mL
Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation
ng/mLLCP-TacroPrograf
Cmax30.08 ± 14.2718.98 ± 6.59
C249.11 ± 2.867.54 ± 2.50
PrimaryPharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (Cmax and C24) was evaluated on Day 28 in adult de novo kidney recipients.

Time frame:
28 days
Reported as:
Mean · ng/mL
Pharmacokinetics (Cmax and C24) of LCP-Tacro Compared to Prograf After Kidney Transplantation
ng/mLLCP-TacroPrograf
Cmax32.51 ± 18.7417.38 ± 4.07
C249.31 ± 3.446.75 ± 2.22
PrimaryPharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (Tmax) was evaluated on Day 1 in adult de novo kidney recipients.

Time frame:
1 days
Reported as:
Mean · hour
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation
hourLCP-TacroPrograf
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation11.26 ± 7.497.39 ± 6.37
PrimaryPharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (Tmax) was evaluated on Day 14 in adult de novo kidney recipients.

Time frame:
14 days
Reported as:
Mean · hour
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation
hourLCP-TacroPrograf
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation7.03 ± 5.695.03 ± 5.81
PrimaryPharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (Tmax) was evaluated on Day 28 in adult de novo kidney recipients.

Time frame:
28 days
Reported as:
Mean · hour
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation
hourLCP-TacroPrograf
Pharmacokinetics (Tmax) of LCP-Tacro Compared to Prograf After Kidney Transplantation5.69 ± 4.117.69 ± 6.87
PrimaryPharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (Fluctuation) was evaluated on Day 14 in adult de novo kidney recipients.

Time frame:
14 days
Reported as:
Mean · Percentage of fluctuation
Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation
Percentage of fluctuationLCP-TacroPrograf
Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation126.86 ± 57.65114.73 ± 52.36
PrimaryPharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation

The pharmacokinetic parameter (Fluctuation) was evaluated on Day 28 in adult de novo kidney recipients.

Time frame:
28 days
Reported as:
Mean · Percentage of fluctuation
Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation
Percentage of fluctuationLCP-TacroPrograf
Pharmacokinetics (Fluctuation) of LCP-Tacro Compared to Prograf After Kidney Transplantation144.78 ± 84.63131.4 ± 75.96
Other pre-specifiedRatio of Nighttime to Daytime Systolic Blood Pressure (SBP) on Day 14.

At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 14.

Time frame:
14 days
Reported as:
Mean · ratio
Ratio of Nighttime to Daytime Systolic Blood Pressure (SBP) on Day 14.
ratioLCP-TacroPrograf
Night:Day ratio SBP0.99 ± 0.0351.01 ± 0.057
Overnight:Day Ratio SBP1.00 ± 0.0531.01 ± 0.057
Other pre-specifiedRatio of Nighttime to Daytime Systolic Blood Pressure (SBP) on Day 28.

At selected sites, a 24-hour measurement of blood pressure will be performed to assess the variability (ei, "nighttime dipping") between the two Groups at Days 28.

Time frame:
28 days
Reported as:
Mean · ratio
Ratio of Nighttime to Daytime Systolic Blood Pressure (SBP) on Day 28.
ratioLCP-TacroPrograf
Night:Day ratio SBP0.99 ± 0.0350.98 ± 0.067
Overnight:Day Ratio SBP0.99 ± 0.0640.98 ± 0.067
Other pre-specifiedEvaluation of the Short-term Efficacy of LCP-Tacro After the Start of Dosing.

The efficacy is measured by the number of treatment failures defined as all-cause mortality, Graft Failure, Biopsy Proven Acute Rejection (BPAR) and Lost to follow up.

Time frame:
30 days
Reported as:
Number · participants
Evaluation of the Short-term Efficacy of LCP-Tacro After the Start of Dosing.
participantsLCP-TacroPrograf
All-cause mortality00
Graft Failure00
BPAR20
Lost to follow up00

Adverse events

Collected over Adverse events were collected from start of study drug and until 30 days after last dose of study drug for at total of 2 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LCP-Tacro—5/17 (29.4%)17/17 (100%)
Prograf—5/17 (29.4%)17/17 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventLCP-TacroPrograf
Kidney transplant rejectionImmune system disorders2/170/17
Angina PectorisCardiac disorders1/170/17
Atrial FibrilationCardiac disorders1/170/17
Ventricular TachycardiaCardiac disorders0/171/17
NauseaGastrointestinal disorders1/171/17
VomitingGastrointestinal disorders1/171/17
Pelvic AbscessInfections and infestations1/170/17
SepsisInfections and infestations0/171/17
Wound infectionInfections and infestations0/171/17
Toxicity to various agentsInjury, poisoning and procedural complications0/171/17
Most frequent other events
Showing 10 of 97
Most frequent other events
EventLCP-TacroPrograf
ConstipationGastrointestinal disorders6/177/17
DiarrhoeaGastrointestinal disorders4/172/17
Oedema peripheralGeneral disorders4/170/17
TremorNervous system disorders4/172/17
HypertensionVascular disorders2/174/17
FlatulenceGastrointestinal disorders3/171/17
NauseaGastrointestinal disorders2/173/17
Blood creatinine increasedInvestigations3/173/17
HyperkalaemiaMetabolism and nutrition disorders3/170/17
HypomagnesaemiaMetabolism and nutrition disorders3/171/17

Baseline characteristics

The two patients that were randomized but not does (one in eacj treatment arm) are not included in the demographics

Age, Categorical
Age, Categorical(Participants)LCP-TacroPrografTotal
<=18 years000
Between 18 and 65 years161632
>=65 years112
Age, Continuous
Age, Continuous(years)LCP-TacroPrografTotal
Mean51.5 ± 13.9246.4 ± 11.4949.0 ± 12.84
Sex: Female, Male
Sex: Female, Male(Participants)LCP-TacroPrografTotal
Female3811
Male14923
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LCP-TacroPrografTotal
Hispanic or Latino145
Not Hispanic or Latino161329
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LCP-TacroPrografTotal
American Indian or Alaska Native101
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American5510
White101222
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)LCP-TacroPrografTotal
United States171734
08

Study locations

13 sites
  • Clinical Investigative Site 000015
    San Diego, California 92123, United States
  • Clinical Investigative Site 000012
    San Francisco, California 94115, United States
  • Clinical Investigative Site 00004
    Aurora, Colorado 80045, United States
  • Clinical Investigative Site 000002
    Tampa, Florida 33606, United States
  • Clinical Investigative Site 000005
    Lexington, Kentucky 40536-0293, United States
  • Clinical Investigative Site 000009
    Ann Arbor, Michigan 48109, United States
  • Clinical Investigative Site 000010
    Livingston, New Jersey 07039, United States
  • Clinical Investigative Site 000011
    Buffalo, New York 14215, United States
  • Clinical Investigative Site 00006
    New York, New York 10016, United States
  • Clinical Investigative Site 00008
    Cleveland, Ohio 44095, United States
  • Clinical Investigative Site 00003
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Investigative Site 000013
    Dallas, Texas 75246, United States
  • Clinical Investigative Site 00001
    Charlottesville, Virginia 22903, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Mar 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2012
First posted
Aug 16, 2012
Start
Nov 2012
Primary completionActual
Mar 2013
CompletionActual
May 2013
Results first posted
Jul 7, 2015
Last update
Jul 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01666951
Lead sponsor
Veloxis Pharmaceuticals
Responsible party
Sponsor
First posted
Aug 16, 2012
Start date
Nov 2012
Primary completion
Mar 2013
Completion
May 2013
Results posted
Jul 7, 2015
Last update
Jul 7, 2015

Study contacts

William Polvino, MD
study director · Veloxis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion